HepElimination

International

Registration and information: www.virology-education.com

PROGRAM COMMITTEE

Charles Boucher, MD, PhDErasmus Medical Center,The Netherlands

Jordan Feld, MD (co-chair 2016) University of Toronto, Toronto Western Hospital Liver Centre, Canada

Manal El-Sayed, MDAin Shams University CairoEgypt

Margeret Hellard, MBBS, PhDBurnet Institute & The Alfred Hospital Melbourne

John Ward, MDCenters of Disease Control and Prevention, USA

Stefan Zeuzem, MDJ.W. Goethe University Hospital, Germany

DEAR COLLEAGUES,

It is our pleasure to invite you for the International Viral Hepatitis Elimination Meeting 2016.

The field of viral hepatitis treatment is undergoing major changes and is on the verge of a paradigm shift. There are great hopes for the elimination of viral Hepatitis. The many new treatment options that are becoming available through the introduction of Direct Acting Antivirals are providing great hopes for decreasing the burden of disease and simplifying treatment and ultimately the elimination of viral Hepatitis.

Commit yourself to help eliminate viral hepatitis and join us at the International Viral Hepatitis Elimination Meeting 2016.

MEETING OBJECTIVES

• Identify the roadblocks and the challenges to come to an integrated approach to eliminate viral hepatitis.

• Identify the needs from the public health perspective.

• Get a cross-disciplinary discussion started.

• Create a platform for collaboration and national action plans.

WHY SHOULD YOU ATTEND?

The workshop provides a cross-disciplinary platform for information exchange between various experts involved in the treatment of Hepatitis-infected patients. Your participation is essential in order to identify and take the necessary steps to eliminate viral Hepatitis.

WHO SHOULD ATTEND?

Medical professionals, including but not limited to Clinicians, Researchers, Public Health representatives, Industry representatives, who look beyond the individual patient and who would like to be involved in the elimination of viral Hepatitis.

Goal: Defining and implementing the pathway forward to eliminate viral hepatitis

ELIMINATION OF VIRAL HEPATITIS

3RD INTERNATIONAL MEETING ON

AMSTERDAM, THE NETHERLANDS • 1-2 DECEMBER 2016

Registration and information: www.virology-education.com

PRELIMINARY PROGRAMTHURSDAY 1 DECEMBER

13.00h Opening of the workshop

13.15h Opening lecture on WHO programs Marc Bulterys, MD, PhD, Centers of Disease Control and Prevention, USA (tbc)

Session 1: Results of National programs: Barriers & Successes

13.45h National perspectives in Europe - common themes and challengesAngelos Hatzakis, PhD, MSC, University of Athens, Greece

14.15h National Programs - Georgia - tbc

14.30h National Programs - Egypt Manal El-Sayed, MD, Ain Shams University, Egypt

14.45h National Programs - AustraliaMargaret Hellard, MBBS, FRACP, FAFPHM, PhD, Burnet Institute, Australia

15.00h National Programs - USJohn Ward, MD, Centers of Disease Control and Prevention, USA

15.15h Discussion

16.00h Coffee Break

Session 2: Progress towards elimination - Specific Populations

Chair: tbc

16.30h InmatesAndrew Lloyd, MBBS, MD, FRACP, PhD, University of New South Wales, Australia (tbc)

16.50h Children & Pregnant womenManal El-Sayed, MD, Ain Shams University, Egypt (tbc)

17.10h People who inject drugsOlav Dalgard, MD, PhD, Akershus University Hospital, Norway (tbc)

17.30h Discussion

18.00h End of Day 1 - Workshop Dinner

FRIDAY 2 DECEMBER

Session 3: Diagnosing

08.30h WHO Guidelines and Policies of testingPhilippa Easterbrook, WHO, Switzerland (tbc)

08.50h Progess in testing technologiesTeri Roberts, FIND, Switzerland (tbc)

09.10h Challenges in Monitoring (POC)Isabelle Andrieux-Meyer, Médecins Sans Frontières, Switzerland (tbc)

09.30h Challenges in regards to resistanceJean-Michel Pawlotsky, MD, PhD, University of Paris-Est, France (tbc)

09.50h Discussion

10.00h Coffee Break

Session 4: Reducing Transmission and harm

10.30h Global injection prevention WHO (include blood safety) - tbc

11.10h Prevention of infection/reinfection in high risk populationMargaret Hellard, MBBS, FRACP, FAFPHM, PhD, Burnet Institute, Australia

11.50h Creating awareness and sharing the knowledgeFabrice Olivet, Autosupport des Usagers de Drogues (ASUD), France (tbc)

11.30h Can we afford not to treat reinfectionPeter Vickerman, DPhil, University of Bristol, United Kingdom (tbc)

11.50h Discussion

12.15h Lunch

Session 5: Future scenarios for elimination

13.15h Vaccine development and resultsAndrea Cox, MD, PhD, Johns Hopkins School of Medicine, USA (tbc)

13.35h Minimising treatment duration and dosesJordan Feld, MD, MPH, University of Toronto, Canada

13.55h Role of generic drugsAndrew Hill, MD, Liverpool University, UK (tbc)

14.15h "Financial basis"Pierre van Damme, MD, PhD, University of Antwerp, Belgium (tbc)

14.35h Building global capacityJohn Ward, MD, Centers of Disease Control and Prevention, USA

14.35h Round table Discussion

15.00h Program adjournment